Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Critics are skeptical. They believe the move — which some have characterized as privatization — could end up making Gilpin ...

SRMIST has announced the SRMJEEE 2025 phase 3 results, accessible on srmist.edu.in. Candidates can log in with their ...

BDL: The scrip traded lower than the 5-day, 10-, 20-day and 30-day simple moving averages (SMAs) but higher than the 50-day, 100-, 150-day and 200-day SMAs.